Dental management of patients treated with intravenous bisphosphonates. A case report

Autores

  • Keico Graciela Sano Trauth University of São Paulo
  • Marilena Chinali Komesu University of São Paulo
  • Claudia Helena Lovato Silva University of São Paulo
  • Valéria Oliveira Pagnano University of São Paulo
  • Leandro Dorigan de Macedo University of São Paulo
  • Ana Carolina Fragoso Motta University of São Paulo

DOI:

https://doi.org/10.26843/ro_unicid.v25i3.346

Palavras-chave:

Bisphosphonates, Osteonecrosis, Dental care, Mouth rehabilitation.

Resumo

Bisphosphonates are drugs used for the inhibition of osteoclastic bone resorption. Their therapeutic use is indicated for Paget

Downloads

Não há dados estatísticos.

Referências

Bocanegra-Perez MS, Vicente-Barrero M, Sosa-Henriquez M, Rodriguez-Bocanegra E, Liminana-Canal JM, LopezMarquez A, et al.

Bone metabolism and clinical study of 44 patients with bisphosphonate-related osteonecrosis of the jaws. Med Oral Patol Oral Cir Bucal 2012 Nov;17(6):e948-55.

Chadha GK, Ahmadieh A, Kumar SK, Sedghizadeh PP. Osseointegration of dental implants and osteonecrosis of the jaw in patients treated with bisphosphonate therapy: A systematic review. J Oral Implantol 2012 Apr 16;

Almasan HA, Baciut M, Rotaru H, Bran S, Almasan OC, Baciut G. Osteonecrosis of the jaws associated with the use of bisphosphonates. Discussion over 52 cases. Rom J Morphol Embryol 2011 52(4):1233-41

Lorenzo SD, Trapassi A, Corradino B, Cordova A. Histology of the Oral Mucosa in Patients With BRONJ at III Stage: A Microscopic Study Proves the Unsuitability of Local Mucosal Flaps. J Clin Med Res 2013 Feb;5(1):22-5.

Saini A, Saifuddin A. MRI of osteonecrosis. Clin Radiol 2004 Dec;59(12):1079-93.

Zarychanski R, Elphee E, Walton P, Johnston J. Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol 2006 Jan;81(1):73-5. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 2003 Nov 15;21(22):42534.

Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005 Jul 7;353(1):99102; discussion 99-.

Hoff AO, Toth BB, Altundag K, Guarneri V, Adamus A, Nooka AK, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 2006 June;24(18 Supplement 8528):

Hasegawa T, Ri S, Umeda M, Komatsubara H, Kobayashi M, Shigeta T, et al. The observational study of delayed wound healing after tooth extraction in patients receiving oral bisphosphonate therapy. J Craniomaxillofac Surg 2013 Octo;41(7):558-63

Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg 2009 May;67(5 Suppl):2-12.

Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006 May 16;144(10):753-61.

Pozzi S, Marcheselli R, Falorio S, Masini L, Stelitano C, Falcone A, et al. Bisphosphonates-associated osteonecrosis of the jaw: A long-term followup of a series of 35 cases observed by GISL and evaluation of its frequency over time. Am J Hematol 2009 Dec;84(12):850-2

Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003 Sep;61(9):1115-7..

Woo SB, Hande K, Richardson PG. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005 Jul 7;353(1):99-102; discussion 99-.

Dunstan CR, Felsenberg D, Seibel MJ. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol 2007 Jan;4(1):42-55.

Ohba T, Cates JM, Cole HA, Slosky DA, Haro H, Ichikawa J, et al. Pleiotropic effects of bisphosphonates on osteosarcoma. Bone 2014 Jun;63(11020.

Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005 Jul 1;104(1):83-93.

Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009 Jan;20(1):11720.

Mehrotra B, Fantasia J, Ruggiero SL. Outcomes of bisphosphonate-related osteonecrosis of the jaw? Importance of staging and management guidelines: a large single institutional update. J Clin Oncol 2008 28(15 suppl 20526):

Katz H. Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: a report of three cases. J Endod 2005 Nov;31(11):831-4.

Downloads

Publicado

2017-12-01

Edição

Seção

Relato de caso / Case report